Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 15/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941611 | 0.87 | PTPN1 (0.49) | PTPN1 | |
| SCHEMBL2949330 | 0.86 | PTPN1 (0.58) | PTPN1PPARGEYA3TTRESR1 | |
| SCHEMBL6103622 | 0.85 | PTPN1 (0.52) | PTPN1EYA3TTR | |
| SCHEMBL2943700 | 0.85 | PTPN1 (0.66) | PTPN1PPARG | |
| SCHEMBL2949257 | 0.83 | PTPN1 (0.46) | PTPN1 | |
| SCHEMBL2949242 | 0.82 | NR1H4 (0.59) | PTPN1EYA3 | |
| SCHEMBL2941428 | 0.81 | PTPN1 (0.42) | PTPN1 | |
| SCHEMBL2941632 | 0.81 | NR1H4 (0.49) | PTPN1EYA3 | |
| SCHEMBL2947341 | 0.81 | PTPN1 (0.69) | PTPN1 | |
| SCHEMBL2941608 | 0.80 | PTPN1 (0.47) | PTPN1EYA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754747-B2 | Oxazolo-naphthyl acids | WYETH LLC (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1781645-A1 | OXAZOLO-NAPHTHYL ACIDS AS PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1(PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES | Wyeth (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060052348-A1 | Oxazolo-naphthyl acids | WYETH (US) | 2006-03-09 | — | — | US | disclosed |
| WO-2006023865-A1 | OXAZOLO-NAPHTHYL ACIDS AS PLAMINOGEN ACTIVATOR INHIBTOR TYPE-1 (PAI-1) MODULATORS USEFUL IN THE TREATMENT OF THROMBOSIS AND CARDIOVASCULAR DISEASES | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052348-A1 | Oxazolo-naphthyl acids | SERPINE1, SERPINB1, SERPINC1 | PTPN1 1585/4885PPARG 300/4885EYA3 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.